id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1814-0124,FDA,FDA-2014-D-1814,Supplemental Comment from Verax Biomedical Incorporated,Other,Supplemental Comment,2017-08-16T04:00:00Z,2017,8,2017-08-16T04:00:00Z,,2017-08-16T13:56:18Z,,0,0,0900006482a3613c
FDA-2014-D-1814-0119,FDA,FDA-2014-D-1814,Supplemental Comment from AABB,Other,Supplemental Comment,2017-04-12T04:00:00Z,2017,4,2017-04-12T04:00:00Z,,2017-04-12T19:03:48Z,,0,0,090000648254ecb9
FDA-2014-D-1814-0118,FDA,FDA-2014-D-1814,Supplemental Comment from New York Blood Center (NYBC),Other,Supplemental Comment,2017-04-06T04:00:00Z,2017,4,2017-04-06T04:00:00Z,,2017-04-06T19:54:06Z,,0,0,090000648254032d